Table 2.
Maximum AEs Grade 3 or Higher With Treatment Attribution
| AE | Letrozole + Bevacizumab (n = 173) | Letrozole (n = 170) | ||
|---|---|---|---|---|
| No. | % | No. | % | |
| Any AE | ||||
| Grade 3 | 71 | 42 | 21 | 13 |
| Grade 4 | 7 | 4.2 | 1 | 0.6 |
| Grade 5 | 1 | 0.6 | 1 | 0.6 |
| Nonhematologic events | ||||
| Grade 3 | 68 | 41 | 21 | 13 |
| Grade 4 | 7 | 4.2 | 1 | 0.6 |
| Grade 5 | 1 | 0.6 | 1 | 0.6 |
| Hematologic events | ||||
| Grade 3 | 5 | 3.0 | 0 | |
| Grade 4 | 0 | 0 | ||
| Grade 5 | 0 | 0 | ||
| Treatment-related death | 1* | 0.6 | 1† | 0.6 |
NOTE. Reported adverse events (AEs) were graded by using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3 with attribution possibly, probably, or definitely related to treatment.
*
CNS hemorrhage.
†
Pneumonia.